Altimmune's Pemvidutide Phase 2b Data
Analysis based on 6 articles · First reported May 28, 2026 · Last updated May 28, 2026
The positive 48-week data from the IMPACT Phase 2b trial for pemvidutide is expected to significantly boost investor confidence in Altimmune, potentially leading to an increase in its stock price. The planned initiation of the PERFORMA Phase 3 trial further solidifies Altimmune's position in the biopharmaceutical market, especially in the treatment of serious liver diseases.
Altimmune announced new 48-week data from its IMPACT Phase 2b trial for pemvidutide, a balanced glucagon/GLP-1 dual receptor agonist, at the European Association for the Study of the Liver (EASL) Congress 2026. The data showed significant reductions in triglycerides (-23.7%) and total cholesterol (-15.4%), along with improvements in weight (-7.5%), waist circumference (-5.3 cm), and blood pressure in patients with metabolic dysfunction-associated steatohepatitis (MASH). The safety profile of pemvidutide was maintained, with a generally favorable tolerability profile. Mazen Noureddin, the IMPACT trial principal investigator, highlighted the broad metabolic impact of pemvidutide, which is highly relevant for MASH patients where cardiovascular disease is a leading cause of mortality. Christophe Arbet-Engels, Chief Medical Officer of Altimmune, expressed confidence in pemvidutide's unique mechanism. The United States — Food and Drug Administration previously granted Fast Track designations for MASH and alcohol use disorder (AUD), and Breakthrough Therapy Designation for MASH. Altimmune plans to initiate the PERFORMA Phase 3 trial for MASH in the second half of 2026.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard